氯吡格雷联合阿托伐他汀对急性脑梗死患者血清高敏C反应蛋白及血脂的影响
|
摘要
目的探讨氯吡格雷联合阿托伐他汀对急性脑梗死患者血清高敏C反应蛋白及血脂的影响。方法选取2017年1月～2018年1月于我院住院治疗的80例急性脑梗死患者作为研究对象,所有患者采用不同治疗方法随机分为观察组和对照组,每组各40例,两组患者均予抗凝、控制脑水肿、胰岛素控制血糖、降压及保护脑组织细胞等常规治疗,阿司匹林抗血小板治疗。观察组同时予以氯吡格雷75 mg/次,每天3次,阿托伐他汀10 mg/次,每天3次,两组均连续治疗14 d。比较两组患者治疗前后血清高敏C反应蛋白及血脂水平。结果治疗后,观察组患者治疗后的hs-CRP水平为(6.45±1.22)mg/L,对照组患者治疗后的hs-CRP水平为(9.61±1.32)mg/L,两组患者治疗后hs-CRP水平比较,差异具有统计学意义(P<0.05)。治疗后,观察组患者治疗后的TC水平为(3.42±0.73)mmol/L,TG为(1.42±0.13)mmol/L,LDL-C为(2.13±0.11)mmol/L,HDL-C为(1.40±0.21)mmol/L,对照组患者治疗后TC水平为(4.12±0.25)mmol/L,TG为(1.63±0.31)mmol/L,LDL-C为(2.57±0.25)mmol/L,HDL-C为(1.13±0.31)mmol/L,两组比较,差异具有统计学意义(P<0.05)。结论氯吡格雷联合阿托伐他汀可降低急性脑梗死患者血清高敏C反应蛋白,调节血脂水平,从而抑制炎症反应,提高临床疗效。
Objective To investigate the effects of clopidogrel combined with atorvastatin on serum high-sensitivity Creactive protein and blood lipids in patients with acute cerebral infarction. Methods A total of 80 patients with acute cerebral infarction who were hospitalized in our hospital from January 2017 to January 2018 were enrolled. All patients were randomly divided into observation group and control group, with 40 cases in each group. Both groups were treated with conventional treatment including anticoagulant, the control of brain edema, the control of blood sugar by insulin,lowering blood pressure and protection of brain tissue cells, and aspirin antiplatelet therapy. The observation group was given clopidogrel 75 mg/time, 3 times a day, atorvastatin 10 mg/time, 3 times a day at the same time. The two groups were treated continuously for 14 d. Serum high-sensitivity C-reactive protein and blood lipid levels were compared before and after treatment in the two groups. Results After treatment, the hs-CRP level of the observation group was(6.45±1.22) mg/L after treatment, and the hs-CRP level of the control group after treatment was(9.61±1.32) mg/L. The difference of hs-CRP levels between two groups after treatment was significant(P<0.05). After treatment, the TC, TG, LDLC and HDL-C of the observation group were(3.42±0.73) mmol/L,(1.42±0.13) mmol/L,(2.13±0.11) mmol/L and(1.40±0.21) mmol/L, respectively, while the TC, TG, LDL-C and HDL-C of the control group was(4.12±0.25) mmol/L,(1.63±0.31) mmol/L,(2.57±0.25) mmol/L, and(1.13±0.31) mmol/L, respectively. The difference between two groups was significant(P<0.05). Conclusion Clopidogrel combined with atorvastatin can reduce serum high-sensitivity C-reactive protein and regulate blood lipid levels in patients with acute cerebral infarction, thereby inhibiting inflammatory response and improving clinical efficacy.
Objective To investigate the effects of clopidogrel combined with atorvastatin on serum high-sensitivity Creactive protein and blood lipids in patients with acute cerebral infarction. Methods A total of 80 patients with acute cerebral infarction who were hospitalized in our hospital from January 2017 to January 2018 were enrolled. All patients were randomly divided into observation group and control group, with 40 cases in each group. Both groups were treated with conventional treatment including anticoagulant, the control of brain edema, the control of blood sugar by insulin,lowering blood pressure and protection of brain tissue cells, and aspirin antiplatelet therapy. The observation group was given clopidogrel 75 mg/time, 3 times a day, atorvastatin 10 mg/time, 3 times a day at the same time. The two groups were treated continuously for 14 d. Serum high-sensitivity C-reactive protein and blood lipid levels were compared before and after treatment in the two groups. Results After treatment, the hs-CRP level of the observation group was(6.45±1.22) mg/L after treatment, and the hs-CRP level of the control group after treatment was(9.61±1.32) mg/L. The difference of hs-CRP levels between two groups after treatment was significant(P<0.05). After treatment, the TC, TG, LDLC and HDL-C of the observation group were(3.42±0.73) mmol/L,(1.42±0.13) mmol/L,(2.13±0.11) mmol/L and(1.40±0.21) mmol/L, respectively, while the TC, TG, LDL-C and HDL-C of the control group was(4.12±0.25) mmol/L,(1.63±0.31) mmol/L,(2.57±0.25) mmol/L, and(1.13±0.31) mmol/L, respectively. The difference between two groups was significant(P<0.05). Conclusion Clopidogrel combined with atorvastatin can reduce serum high-sensitivity C-reactive protein and regulate blood lipid levels in patients with acute cerebral infarction, thereby inhibiting inflammatory response and improving clinical efficacy.
引文
[1]朱杰权,许晓跃,诸苏杭,等.阿托伐他汀钙联合氢氯吡格雷治疗急性脑梗死患者颈动脉粥样硬化斑块效果观察[J].中国现代医生,2013,51(14):91-92.
[2]杨帆,丁伯平.他汀类药物的应用进展及存在问题[J].中外医学研究,2012,10(2):163-164.
[3]刘丽,张英岚,陶利勇,等.大剂量阿托伐他汀在急性脑梗死治疗中的应用[J].临床合理用药,2014,7(7):96-97.
[4]梁栋.氯吡格雷联合阿托伐他汀钙治疗脑梗死临床观察[J].中国医疗前沿,2013,8(21):64-65.
[5]王建法,贾帅.阿托伐他汀对急性脑梗死患者炎性细胞因子及神经功能缺损的影响[J].中国医药,2012,7(9):1089-1090.
[6]贺文敏.氯吡格雷联合阿托伐他汀钙在预防TIA后脑梗死中的临床应用[J].实用药物与临床,2014,17(4):409-410.
[7]牛文亮,张茂.氯吡格雷联合阿托伐他汀钙治疗急性脑梗死疗效观察[J].包头医学院学报,2013,29(5):37-38.
[8]张建丽.氯吡格雷联合阿托伐他汀对急性脑梗死患者血清高敏C反应蛋白及血脂的影响[J].山西医药杂志,2010,39(11A):1087.
[9]吴卫,卢理英,邹颖.阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的临床观察[J].海峡药学,2012,24(5):204-205.
[10]蔡敏,马碌曦,罗春阳,等.阿托伐他汀对急性脑梗死患者颈动脉粥样硬化斑块的影响[J].重庆医学,2012,41(7):656-657,660.
[11]刘宏.氯吡格雷对脑梗死患者预后的影响作用研究[J].当代医学,2012,18(23):141-142.
[12]陈颖,王志海,陈文荣,等.氯吡格雷联用阿托伐他汀预防高危患者脑梗死再发前瞻性研究[J].河北医学,2010,16(1):10-11.
[13]卓建明,卢良春,管晓斌,等.阿托伐他汀强化降脂对急性脑梗死患者的疗效及血脂和血清炎性因子水平影响[J].中国药师,2015,18(10):1779-1781.
[14]庞伟,周琛,麦超,等.阿托伐他汀钙联合氯吡格雷预防TIA发作后脑梗死的作用及对血脂水平、凝血功能的影响[J].中国医药科学,2018,8(3):70-72.
[15]沈艳娜.氯吡格雷联合阿托伐他汀治疗脑梗死的临床效果[J].当代医学,2016,22(25):132-133.
[16]申春云,梁洁,岑磊,等.氯吡格雷联合强化阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的效果观察[J].中国医药科学,2016,6(18):50-53.
[17]张元元.阿托伐他汀强化降脂对急性脑梗患者疗效及血脂水平的影响[J].淮海医药,2018,36(1):92-94.
[18]张东照.氯吡格雷联合阿托伐他汀钙治疗脑梗塞的效果观察[J].北方药学,2016,13(11):71-72.
[19]薛红霞.氯毗格雷治疗67例脑梗死的临床疗效分析[J].临床医学工程,2011,18(11):1752-1753.
[20]张建丽.氯吡格雷联合阿托伐他汀对急性脑梗死患者血清高敏C反应蛋白及血脂的影响[J].山西医药杂志,2010,39(11):1087-1082.
[21]王红岩.氯吡格雷联合阿托伐他汀治疗急性脑梗死的疗效及对血清hs-CRP的影响[J].中国现代医生,2016,54(5):29-31.
[2]杨帆,丁伯平.他汀类药物的应用进展及存在问题[J].中外医学研究,2012,10(2):163-164.
[3]刘丽,张英岚,陶利勇,等.大剂量阿托伐他汀在急性脑梗死治疗中的应用[J].临床合理用药,2014,7(7):96-97.
[4]梁栋.氯吡格雷联合阿托伐他汀钙治疗脑梗死临床观察[J].中国医疗前沿,2013,8(21):64-65.
[5]王建法,贾帅.阿托伐他汀对急性脑梗死患者炎性细胞因子及神经功能缺损的影响[J].中国医药,2012,7(9):1089-1090.
[6]贺文敏.氯吡格雷联合阿托伐他汀钙在预防TIA后脑梗死中的临床应用[J].实用药物与临床,2014,17(4):409-410.
[7]牛文亮,张茂.氯吡格雷联合阿托伐他汀钙治疗急性脑梗死疗效观察[J].包头医学院学报,2013,29(5):37-38.
[8]张建丽.氯吡格雷联合阿托伐他汀对急性脑梗死患者血清高敏C反应蛋白及血脂的影响[J].山西医药杂志,2010,39(11A):1087.
[9]吴卫,卢理英,邹颖.阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的临床观察[J].海峡药学,2012,24(5):204-205.
[10]蔡敏,马碌曦,罗春阳,等.阿托伐他汀对急性脑梗死患者颈动脉粥样硬化斑块的影响[J].重庆医学,2012,41(7):656-657,660.
[11]刘宏.氯吡格雷对脑梗死患者预后的影响作用研究[J].当代医学,2012,18(23):141-142.
[12]陈颖,王志海,陈文荣,等.氯吡格雷联用阿托伐他汀预防高危患者脑梗死再发前瞻性研究[J].河北医学,2010,16(1):10-11.
[13]卓建明,卢良春,管晓斌,等.阿托伐他汀强化降脂对急性脑梗死患者的疗效及血脂和血清炎性因子水平影响[J].中国药师,2015,18(10):1779-1781.
[14]庞伟,周琛,麦超,等.阿托伐他汀钙联合氯吡格雷预防TIA发作后脑梗死的作用及对血脂水平、凝血功能的影响[J].中国医药科学,2018,8(3):70-72.
[15]沈艳娜.氯吡格雷联合阿托伐他汀治疗脑梗死的临床效果[J].当代医学,2016,22(25):132-133.
[16]申春云,梁洁,岑磊,等.氯吡格雷联合强化阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的效果观察[J].中国医药科学,2016,6(18):50-53.
[17]张元元.阿托伐他汀强化降脂对急性脑梗患者疗效及血脂水平的影响[J].淮海医药,2018,36(1):92-94.
[18]张东照.氯吡格雷联合阿托伐他汀钙治疗脑梗塞的效果观察[J].北方药学,2016,13(11):71-72.
[19]薛红霞.氯毗格雷治疗67例脑梗死的临床疗效分析[J].临床医学工程,2011,18(11):1752-1753.
[20]张建丽.氯吡格雷联合阿托伐他汀对急性脑梗死患者血清高敏C反应蛋白及血脂的影响[J].山西医药杂志,2010,39(11):1087-1082.
[21]王红岩.氯吡格雷联合阿托伐他汀治疗急性脑梗死的疗效及对血清hs-CRP的影响[J].中国现代医生,2016,54(5):29-31.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |